Historical mrk News Stories

Merck Surge: FDA Wins, MFN Deal, EXZOLT Boost Now!

Merck (MRK) saw several concrete catalysts this week: two FDA Priority Review vouchers for late-stage human drugs, a Most-Favored-Nation pricing pact with U.S. authorities, conditional FDA approval for a new cattle parasiticide, and financing tied to a strategic acquisition. Those events tighten approval timelines, clarify pricing risk, and strengthen the animal-health revenue base — factors that materially affect MRK’s near-term valuation and investor outlook.

Merck: Winrevair Lifts MRK; Keytruda Injunction

This week Merck (MRK) saw regulatory wins and legal setbacks: the EMA committee recommended expanding Winrevair for PAH, a German court blocked distribution of subcutaneous Keytruda, Merck’s animal-health unit secured conditional FDA approval for Exzolt in cattle, and Q3 results beat expectations—shaping near-term investor prospects.

Mercks EXZOLT Approval Boosts Animal Health Gains

Merck’s Animal Health unit secured an FDA conditional approval for EXZOLT CATTLE‑CA1 to control New World screwworm and cattle fever tick, creating a near-term product launch opportunity in Q1 2026. Strong Q2/Q3 animal health revenue and planned manufacturing investments underpin long-term growth, even as MRK shares showed muted market reaction in the past week.

Merck Boosted by U.K. Drug-Price Deal, Animal Edge

Merck (MRK) stands to benefit from a recent U.S.–U.K. agreement that raises U.K. prices for new patented medicines and offers tariff relief, strengthening its European revenue outlook and operational footing. At the same time, Merck’s animal-health business showed relative resilience versus Zoetis, supporting investor confidence in MRK within the DJ30.

Merck Rally: HIV Win, Keytruda SC, Dow Leadership!

Merck surged this week after a Phase III win for an oral two‑drug HIV regimen and European approval for Keytruda subcutaneous dosing. Those concrete clinical and regulatory milestones powered MRK stock gains that meaningfully lifted the Dow, offering investors short‑term momentum and tangible long‑term catalysts.

Merck Q3 Beats; Verona Deal, Guidance Trim Ahead!!

Merck delivered a strong Q3 led by Keytruda and Winrevair, closed the Verona Pharma acquisition for Ohtuvayre, and tightened full‑year revenue guidance — a mix that drove stock reaction even as pipeline approvals and manufacturing investments support longer‑term growth.

Merck Stretches into Obesity; Cuts Oncology Bets Now

Merck (MRK) this week struck a licensing deal to enter obesity therapeutics, paused several late‑stage oncology programs, and gained regulatory momentum in other areas. The Hansoh partnership for preclinical GLP‑1 candidate HS‑10535, EMA's favorable opinion for Welireg, and an RSV prophylactic filing highlight a strategic refocus that could reshape near‑term expectations for MRK stock.